Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction

American Journal of Medicine

Volumn 114, Issue 1, 2003, Pages 25-30

  Omland, Torbjørn ^a   Dickstein, Kenneth ^b   Syversen, Unni ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; POLYPEPTIDE;

ADULT; AGE; AGED; ARTICLE; CIRCULATION; CLINICAL FEATURE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; GENDER; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SAMPLING;

EID: 0037245412     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01425-0     Document Type: Article

References (36)

1. Cohn J.N., Levine T.B., Olivary M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 311:1984;819-823.
2. Francis G.S., Cohn J.N., Johnson G., et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effect of therapy in V-HeFT II. Circulation. 87:(suppl VI):1993;40-48.
3. Benedict C.R., Shelton B., Johnstone D.E., et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation. 94:1996;690-697.
4. Jewitt D.E., Reid D., Thomas M., et al. Free noradrenaline and adrenaline excretion in relation to the development of cardiac arrhythmias and heart-failure in patients with acute myocardial infarction. Lancet. i:1969;635-641.
5. Omland T., Aarsland T., Aakvaag A., et al. Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. Am J Cardiol. 72:1993;255-259.
6. Rouleau J.L., Packer M., Moye L., et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction effect of captopril . J Am Coll Cardiol. 24:1994;583-591.
7. Helle K.B. Some chemical and physical properties of the soluble protein fraction of bovine adrenal chromaffin granules. Mol Pharmacol. 2:1966;298-310.
8. Smith A.D., Winkler H. Purification and properties of an acidic protein from chromaffin granules of bovine adrenal medulla. Biochem J. 103:1967;483-492.
9. O'Connor D.T., Frigon R.P. Chromogranin A, the major catecholamine storage vesicle soluble protein. J Biol Chem. 259:1984;3237-3247.
10. Takiyyuddin M.A., Cervenka J.H., Sullivan P.A., et al. Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation. 81:1990;185-195.
11. O'Connor D.T. Chromogranin A widespread immunoreactivity in polypeptide hormone producing tissues and in serum . Regul Pept. 6:1983;263-280.
12. Lloyd R.V., Wilson B.S. Specific endocrine tissue marker defined by a monoclonal antibody. Science. 222:1983;628-630.
13. O'Connor D.T., Bernstein K.N. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and in patients with pheochromocytoma. N Engl J Med. 311:1984;764-770.
14. O'Connor D.T., Deftos L.J. Secretion of chromogranin A by peptide producing endocrine neoplasms. N Engl J Med. 314:1986;1145-1151.
15. Syversen U., Jacobsen M.B., Hanssen L.E., et al. Chromogranin A and pancreastatin-like immunoreactivity in human carcinoid disease. Eur J Gastroenterol Hepatol. 5:1993;1043-1050.
16. Hsiao R.J., Seeger R.C., Yu A.L., O'Connor D.T. Chromogranin A in children with neuroblastoma. J Clin Invest. 85:1990;1555-1559.
17. O'Connor D.T. Plasma chromogranin A initial studies in human hypertension . Hypertension. 7:1985;176-179.
18. Takiyyuddin M.A., Cervenka J.H., Hsiao R.J., et al. Chromogranin A. Storage and release in hypertension. Hypertension. 15:1990;237-246.
19. Takiyyuddin M.A., De Nicola L., Gabbai F.B., et al. Catecholamine secretory vesicles. Augmented chromogranins and amines in secondary hypertension. Hypertension. 21:1993;674-679.
20. Takiyyuddin M.A., Parmer R.J., Kailasam M.T., et al. Chromogranin A in human hypertension. Influence of heredity. Hypertension. 26:1995;213-220.
21. Corti A., Ferrari R., Ceconi C. Chromogranin A and tumor necrosis factor-alpha (TNF) in chronic heart failure. Adv Exp Med Biol. 482:2000;351-359.
22. O'Connor D.T., Pandian M.R., Carlton E., et al. Rapid radioimmunoassay of circulating chromogranin A in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure . Clin Chem. 35:1989;1631-1637.
23. Syversen U., Jacobsen M.B., O'Connor D.T., et al. Immunoassay for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides. 26:1994;201-206.
24. Swedberg K., Held P., Kjekshus J., et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med. 327:1992;678-684.
25. Omland T., Lie R.T., Aakvaag A., et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 89:1994;1573-1579.
26. Omland T., Aakvaag A., Bonarjee V.V.S., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation. 93:1996;1963-1969.
27. Causon R.C., Carruthers M.E., Rodnight R. Assay of plasma catecholamines by liquid chromatography with electrochemical detection. Anal Biochem. 116:1981;223-226.
28. Takiyyuddin M.A., Baron A.D., Cervenka J.H., et al. Suppression of chromogranin-A release from neuroendocrine sources in man pharmacological studies . J Clin Endocrinol Metab. 72:1991;616-622.
29. Steiner H.-J., Weiler R., Ludescher C., et al. Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J Histochem Cytochem. 38:1990;845-850.
30. Richards A.M., Nicholls M.G., Yandle T.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 97:1998;1921-1929.
31. Cryer P.E., Wortsman J., Shah S.D., et al. Plasma chromogranin A as a marker of sympathochromaffin activity in humans. Am J Physiol. 260:1991;E243-E246.
32. Takiyyuddin M.A., Neumann H.P., Cervenka J.H., et al. Ultradian variations of chromogranin A in humans. Am J Physiol. 261:1991;R939-R944.
33. Galindo E., Rill A., Bader M.F., Aunias D. Chromostatin, a 20 amino acid peptide derived from chromogranin A, inhibits chromaffin cell secretion. Proc Natl Acad Sci USA. 88:1991;1426-1430.
34. Galindo E., Zwiller J., Bader M.F., Aunis D. Chromostatin inhibits catecholamine secretion in adrenal chromaffin cells by activating a protein phosphatase. Proc Natl Acad Sci USA. 89:1992;7398-7402.
35. Aardal S., Helle K.B. The vasoinhibitory activity of bovine chromogranin A (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept. 41:1992;9-18.
36. Kennedy B.P., Mahata S.K., O'Connor D.T., Ziegler M.G. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides. 19:1998;1241-1248.